RetiSpec Secures $10M in Series A Funding to Advance AI-Driven Eye Diagnostics for Alzheimer's Detection
RetiSpec Inc. is at the forefront of integrating AI and medical technology to combat neurodegenerative diseases through early detection methods.
Company Name: RetiSpec Inc.
Location: Toronto, Canada
Sector: Health Tech, AI Diagnostics
Funding Details: Raised $10 million USD in Series A funding, bringing total funding to $17 million USD. The round was led by iGan Partners, with strategic investments from Eli Lilly and Company and Topcon Healthcare, Inc. Additional support came from Gentex Corporation, the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator, Verge HealthTech Fund, University of Minnesota’s Discovery Capital, Ontario Brain Institute, Centre for Aging + Brain Health Innovation, and private investors.
Purpose of Investment: The funding will be used to accelerate the commercialization of RetiSpec’s technology, which focuses on the early detection of Alzheimer’s disease through innovative eye diagnostic tools.
Leadership: Led by Eliav Shaked, Co-founder and CEO.
Product and Innovation: RetiSpec specializes in AI-driven eye diagnostics that enable early and accurate detection of neurodegenerative disease markers through non-invasive retinal imaging. The company's flagship AI technology provides real-time diagnostic results at the point of care, focusing on predicting amyloid burden as an aid in evaluating individuals for Alzheimer’s disease. Currently, RetiSpec’s AI solutions are available for Research Use Only.
Company Growth: With the new funds, RetiSpec aims to push forward the commercial availability of its groundbreaking diagnostic solutions, aiming to transform how neurodegenerative diseases like Alzheimer’s are detected and managed at early stages, potentially improving outcomes for millions worldwide.
About the Company: RetiSpec Inc. is at the forefront of integrating AI and medical technology to combat neurodegenerative diseases through early detection methods. Their innovative approach leverages the accessibility of eye exams to predict disease markers, making critical diagnostic tools more widely available and potentially altering the course of Alzheimer’s disease management.